Boston Biomedical, Inc. is a leading developer of novel cancer therapeutics with the goal of significantly improving patient outcomes. As a fully integrated oncology drug research and development company, Boston Biomedical, Inc. has established a track record of accomplishments, including advancing the research and development of multiple compounds and clinical programs. The company’s range of expertise includes drug discovery, external innovation partnerships, medicinal chemistry, preclinical development, pharmacology, pharmaceutical development, CMC (chemistry, manufacturing, and control), global clinical trials, regulatory affairs and commercialization. Headquartered in Cambridge, Massachusetts, Boston Biomedical, Inc. has created a unique corporate environment, leveraging its innovation-driven culture, scientific leadership, and drug development expertise to advance the development of novel therapeutics for patients with cancer. Visit https://www.bostonbiomedical.com/careers/ for more information. Boston Biomedical, Inc. is indirectly and wholly owned by Sumitomo Dainippon Pharma Co., Ltd., a pharmaceutical company based in Japan. In 2017, Sumitomo Dainippon Pharma acquired Tolero Pharmaceuticals, a U.S.-based biotechnology company specializing in research and development of therapeutic agents in the areas of oncology and hematological disorders. This acquisition expanded Sumitomo Dainippon Pharma’s global oncology and hematology portfolios. Together, the companies – Sumitomo Dainippon Pharma Co., Ltd., Boston Biomedical and Tolero Pharmaceuticals – work to expedite drug discovery, development and commercialization of innovative treatments for cancer. This collaboration harnesses the expertise of each organization with the goal of significantly improving patient outcomes.
View Top Employees from Boston Biomedical, Inc.Website | https://www.bostonbiomedical.com |
Revenue | $19 million |
Funding | $2 million |
Employees | 48 (48 on RocketReach) |
Founded | 2006 |
Address | 640 Memorial Drive, Cambridge, Massachusetts 02139, US |
Phone | (617) 674-6800 |
Technologies |
JavaScript,
HTML,
Font Awesome
+30 more
(view full list)
|
Industry | Business Services, Biotechnology, Pharmaceutical Manufacturing, Drug Discovery, Cancer research, Science and Engineering, Oncology, Medical, Drug development, Health Care, Cancer stem cells, Therapeutics |
Competitors | Acceleron Pharma, Neuraltus Pharmaceuticals, OncoMed Incorporated, Ortho Biotech Oncology Research and Development, A Unit of Cougar Biotechnology, Verastem Oncology |
SIC | SIC Code 873 Companies, SIC Code 87 Companies |
NAICS | NAICS Code 5417 Companies, NAICS Code 54 Companies, NAICS Code 541 Companies |
Looking for a particular Boston Biomedical, Inc. employee's phone or email?
The Boston Biomedical, Inc. annual revenue was $19 million in 2024.
Lucia Archiable is the Medical Director of Boston Biomedical, Inc..
48 people are employed at Boston Biomedical, Inc..
Boston Biomedical, Inc. is based in Cambridge, Massachusetts.
The NAICS codes for Boston Biomedical, Inc. are [5417, 54, 541].
The SIC codes for Boston Biomedical, Inc. are [873, 87].